Biomatrix Resolves FDA Concerns Over Anti-adhesion Claims For HylaSine
This article was originally published in The Gray Sheet
Executive Summary
Biomatrix removed a March 29 press release announcing approval of the HylaSine sinus gel stent from its website after receiving an FDA warning letter May 24 citing the firm for promotional violations.